Hierarchical multifunctional graphene oxide cancer nanotheranostics agent for synchronous switchable fluorescence imaging and chemical therapy.

Mikrochim Acta

Biosensor Research Center (BRC), Department of Biomaterials, Nanotechnology, and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences (IUMS), Isfahan, Iran.

Published: September 2020

AI Article Synopsis

  • A new nanotheranostics platform using PEGylated graphene oxide-gold nanoparticles and an aptamer targeting MUC-1-positive tumor cells was developed for imaging and therapy of breast and colon cancers.
  • The platform successfully delivered the drug doxorubicin and utilized non-invasive fluorescence imaging, with success evaluated through various characterization techniques.
  • The aptamer functions as a biosensor that activates drug release upon binding to target cells, demonstrating higher toxicity in MUC-1-positive cancer cells compared to negative ones, indicating its potential for targeted cancer treatment.

Article Abstract

A nanotheranostics platform was synthesized based on PEGylated graphene oxide-gold nanoparticles and specified with aptamer toward the MUC-1-positive tumor cells. Subsequently, it was loaded with doxorubicin, used for non-invasive fluorescence imaging and therapy of breast and colon tumors. The success of the nano-coating at each synthesis step was characterized through FTIR, XRD, TGA, FE-SEM, EDAX, Zeta-potential, and fluorescence spectroscopy. Besides, the ability of the designed platform in targeted imaging, drug delivery, and in vitro therapy were evaluated using fluorescence microscopy and flow cytometry. The selected aptamer acts as a quencher, resulting in an "on/off" fluorescence biosensor. When the aptamer specifically binds to the MUC-1 receptor, its double strands separate, leading to the drug release and the recovery of the fluorescence of ("On" state) at the excitation wavelength of 300 nm. Based on cell toxicity results, this platform has more toxicity toward the MUC-1-positive tumor cells (HT-29 and MCF-7) compared  to MUC-1-negative cells (Hep-G2), representing its selective performance. Thus, this nano-platform can be introduced as a multifunctional cancer nanotheranostics system for tracing particular biomarkers, non-invasive imaging, and targeted chemotherapy. Graphical abstract.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00604-020-04490-6DOI Listing

Publication Analysis

Top Keywords

cancer nanotheranostics
8
fluorescence imaging
8
muc-1-positive tumor
8
tumor cells
8
fluorescence
6
hierarchical multifunctional
4
multifunctional graphene
4
graphene oxide
4
oxide cancer
4
nanotheranostics agent
4

Similar Publications

Precision Oncology: Advances in Drug Delivery and Imaging.

Recent Adv Drug Deliv Formul

December 2024

Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Pharmaceutics, Gujarat, India.

The development of precise and reliable cancer treatments has been a long-standing goal in oncology. Conventional therapies often affect healthy tissues, leading to significant side effects. To overcome these challenges, researchers are exploring new methodologies that combine advanced drug delivery systems with state-of-the-art imaging technologies to target tumors more effectively.

View Article and Find Full Text PDF

In treating type 2 diabetes, avoiding glucose reabsorption (glucotoxicity) and managing hyperglycemia are also important. A metabolic condition known as diabetes (type-2) is characterized by high blood sugar levels in comparison to normal Bilosomes (BLs) containing Dapagliflozin (Dapa) were formulated, optimized, and tested for oral therapeutic efficacy in the current investigation. Used the Box Behnken design to optimize the Dapa-BLs, formulated via a thin-film hydration technique.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates a new cancer treatment system called Chit-IOCO-MTX-Cy5, which combines chitosan nanocomposites with cerium oxide and iron oxide nanoparticles, along with methotrexate and a dye for imaging.
  • The system acts as both an anti-cancer agent and enhances MRI imaging, showing high effectiveness with better results than currently approved imaging agents.
  • It significantly reduces tumor growth with no regrowth after treatment, while showing good safety in mice, indicating its potential as an effective cancer theranostic tool.
View Article and Find Full Text PDF

Photothermal therapy (PTT) has garnered significant attention in recent years, but the standalone application of PTT still faces limitations that hinder its ability to achieve optimal therapeutic outcomes. Nitric oxide (NO), being one of the most extensively studied gaseous molecules, presents itself as a promising complementary candidate for PTT. In response, various nanosystems have been developed to enable the simultaneous utilization of PTT and NO-mediated gas therapy (GT), with the integration of photothermal agents (PTAs) and thermally-sensitive NO donors being the prevailing approach.

View Article and Find Full Text PDF

Golden era of radiosensitizers.

Front Vet Sci

December 2024

Department of Radiobiology, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czechia.

The past 30 years have brought undeniable progress in medicine, biology, physics, and research. Knowledge of the nature of the human body, diseases, and disorders has been constantly improving, and the same is true regarding their treatment and diagnosis. One of the greatest advances in recent years has been the introduction of nanoparticles (NPs) into medicine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!